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S U M M A R Y
Objectives: To summarize published data on the clinical and economic burden, epidemiology,
antimicrobial resistance levels, serotype prevalence, and prevention strategies for pneumococcal
disease among adults in Asia.
Methods: We performed a systematic search of the PubMed database for relevant, peer-reviewed articles
published between January 1995 and December 2011, covering China, Hong Kong, India, Indonesia,
Japan, Malaysia, Pakistan, the Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
Results: Taiwan and Thailand had the most comprehensive epidemiological data on adult pneumococcal
disease. Very little relevant data were found for Indonesia, Pakistan, the Philippines, and Vietnam;
surveillance is urgently needed in these countries. The emergence and spread of resistance emphasize
the importance of vaccination to prevent infection in adults at increased risk for serious pneumococcal
disease. Vaccination policies and opinions on the efﬁcacy of vaccination vary widely in Asian countries,
although a new option in the form of a pneumococcal conjugate vaccine is now available.
Conclusions: Increased awareness of the public health and economic beneﬁts of pneumococcal
vaccination is critically needed to help both the public and policymakers in making changes to
vaccination policies in the region. Maximizing access to pneumococcal vaccines will decrease the
number of hospitalizations, complications, and deaths associated with pneumococcal disease.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Streptococcus pneumoniae (pneumococcus) is the most common
cause of community-acquired pneumonia, meningitis, and bacter-
emia in children and adults, including the elderly, and is
responsible for high rates of morbidity and mortality worldwide.
The vast majority of disease-burden data and epidemiological
studies on pneumococcal disease have been reported in child
populations; however, limited data are available regarding the
burden and epidemiology of pneumococcal disease in adults,
particularly in Asia. Importantly, the population of Asia is the
fastest growing population in the world, and identifying key
strategies for combating pneumococcal disease has the greatest
potential public health impact worldwide.* Corresponding author.
E-mail address: ivanhung@hku.hk (I.F.N. Hung).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.01.004The incidence of invasive pneumococcal disease (IPD) is
expected to rise secondary to the increase in the elderly
populations. Groups most at risk of pneumococcal infection
include those of extreme age, immunocompetent persons with
underlying medical conditions (chronic cardiovascular, pulmo-
nary, liver and neurological diseases, and diabetes mellitus), and
individuals with defects of immune defenses or decreased immune
responses (functional or anatomic asplenia, immunosuppressive
conditions, post organ or bone marrow transplantation, or on
therapy with alkylating agents, anti-metabolites, or systemic
corticosteroids).1 Other risk factors include male sex, alcohol
abuse, cigarette smoking, asthma, cerebral spinal ﬂuid leakage,
cochlear implant, recent inﬂuenza infection, institutionalization,
and certain ethnic groups.1
Adult mortality rates for bacteremic pneumococcal pneumonia
range from 10% to 30%, and for meningitis from 16% to 37%.1
Mortality rates are substantially higher in the elderly and in
patients with comorbidities.1 Factors that are associated with
worsened outcomes in some studies include >65 years of age,ses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Process of study selection for the systematic review.
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intensive care, alcohol abuse, chronic cardiac or pulmonary
disease, renal failure, immunosuppressive therapy, and serious
underlying disease.1 Importantly, mortality rates are much higher
in young children in developing countries (10–40%), likely due to
poorer access to health care and comorbidities, particularly HIV
infection and malnutrition. A recent study of >18 000 IPD cases in
Denmark conﬁrmed that age and comorbidities inﬂuence surviv-
al.2 In this cohort, mortality rates were <3% for children younger
than 5 years of age, 14% for individuals aged 5–65 years, and 24%
for adults 65 years of age. These ﬁndings underscore the public
health impact of pneumococcal disease in adult populations.
Pneumococcal vaccines can prevent the development of
antibiotic-resistant infections by reducing the carriage of antibi-
otic-resistant serotypes, limit the spread of pneumococcal disease,
and may decrease the incidence of drug resistance through
reducing the use of antibiotics.3 Licensed pneumococcal vaccines
are currently available for use in adults and children. The 23-valent
pneumococcal polysaccharide vaccine (PPV23), a non-conjugated
polysaccharide vaccine, was ﬁrst licensed in 1983 and is used
almost exclusively in adults.4,5 Three pneumococcal conjugate
vaccines (PCV) are licensed for use in children. The heptavalent
PCV (PCV7) was ﬁrst licensed in the USA in 2000 and is now
available in more than 100 countries worldwide.5 PCV7 contains
poly- or oligosaccharides from seven S. pneumoniae serotypes (4,
6B, 9V, 14, 18C, 19F, and 23F), each conjugated to genetically
detoxiﬁed diphtheria toxin CRM197. A 10-valent PCV (PCV10)
using recombinant non-typeable Haemophilus inﬂuenzae protein D
as the conjugate, was ﬁrst licensed in Canada, Europe, and Australia
in 2009; this vaccine includes serotypes 1, 5, and 7F in addition to
those included in PCV7. In 2009, the 13-valent PCV (PCV13) was
ﬁrst licensed; it includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F, and 23F.
PCVs are approved for use in children all over the world, are
immunogenic in adults, and very recently a PCV13 was approved
for use in many countries including the USA and the countries of
the European Union.6–8 The impact of dual vaccination against S.
pneumoniae and inﬂuenza is also being studied.9,10 To aid
policymakers and health authorities in understanding the clinical
need for adult PCV vaccination and its potential impact, the clinical
and economic burden, epidemiology, antimicrobial resistance
levels, and serotype prevalence of pneumococcal disease among
adults must be known for each individual country or region.
The aim of this review is to provide a summary of all available
English-language data published from January 1995 to December
2011 on pneumococcal disease in adults, including the clinical and
economic burden of disease, available epidemiological data,
current data regarding antimicrobial resistance levels, data
regarding serotype prevalence of pneumococcal isolates, and
current vaccination policies. This review will discuss these
parameters of pneumococcal disease in 13 Asian countries,
including China, Hong Kong, India, Indonesia, Japan, Malaysia,
Pakistan, the Philippines, Singapore, South Korea, Taiwan,
Thailand, and Vietnam. Further, this review will provide sugges-
tions for improving country surveillance in adults and discuss the
impact of antibiotic and vaccine administration in these countries.
2. Methods
2.1. Search strategy
This is a systematic literature review of published data on the
burden, epidemiology, antimicrobial resistance levels, and sero-
type prevalence of pneumococcal disease among adults in Asia.
The data included in this review were published between January
1995 and December 2011, and relate to the following 13 countries:China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, the
Philippines, Singapore, South Korea, Taiwan, Thailand, and
Vietnam.
EndNote version XI (Thomson Reuters) was used to search the
PubMed database for relevant, peer-reviewed articles published
between January 1995 and October 2010. We used three search
strings of differing stringency, repeated for each country,
combining the search terms: country name, pneumonia, Strepto-
coccus, pneumococcal, incidence, and adults, as well as terms
aimed to exclude studies limited to children, animal studies,
vaccine development, and studies primarily related to other
organisms causing pneumonia (Klebsiella and Pneumocystis). A
manual search of PubMed with the same search strings was used to
identify references published between November 2010 and
December 2011, inclusive. We also searched for relevant reports
on the World Health Organization website and on government/
ministry of health websites of individual countries for any reported
available in English. Figure 1 shows a ﬂow diagram of the study
selection process.
2.2. Exclusion criteria
The titles and abstracts of all articles identiﬁed on PubMed by
these searches were scanned for relevance and duplicates were
removed. The full texts of potentially relevant papers were
obtained, critically appraised once more, and the remaining
unsuitable articles were then eliminated. The following types of
article were excluded: case studies; studies in Asian populations
residing outside Asia; pneumococcal vaccine efﬁcacy, immunoge-
nicity, and safety studies; antibiotic efﬁcacy studies; molecular
characterization of bacterial strains; studies involving only
children or infants; studies involving only nosocomial or hospi-
tal-acquired infections; studies on diagnostic, sampling, or
I.F.N. Hung et al. / International Journal of Infectious Diseases 17 (2013) e364–e373e366serotyping methods; animal studies; review articles; studies that
that did not mention S. pneumoniae, but described only other
organisms that cause pneumonia (e.g., Klebsiella pneumoniae,
Mycoplasma pneumoniae, Pneumocystis jiroveci, Pseudomonas aeru-
ginosa, and Pneumocystis carinii); and non-English language articles.
3. Results and discussion
3.1. Incidence and mortality of pneumococcal disease
Studies identiﬁed reporting the incidence and mortality of
pneumococcal disease varied greatly in quality and design, with
differing population demographics. Many study populations were
small (<50–200), in particular for mortality data, were drawn from
a small number (one or two) of urban centers, were published
more than a decade ago, or were published before PCVs became
widely used. The data reviewed here may therefore not be
representative of the current situation in the countries described.
Incidence data for pneumococcal disease were variable in the
type of statistics published, and are available for only ﬁve of the 13
countries surveyed (Hong Kong, Malaysia, Singapore, Taiwan, and
Thailand); a summary of the largest and most recent studies
identiﬁed from PubMed is presented in Table 1. There were no
English-language articles published on incidence data for pneu-
mococcal disease in adults in China, India, Indonesia, Japan,
Pakistan, the Philippines, South Korea, and Vietnam.
The most comprehensive incidence data came from Singapore,
Taiwan, and two provinces of Thailand. Many of the studies
involved hospital-based surveillance and were therefore likely to
underestimate true incidence ﬁgures, as they did not capture
patients not admitted to hospital. In Singapore, a study of 4275
cases of pneumococcal disease (97.9% were pneumococcalTable 1
Summary of the incidence of pneumonia and invasive pneumococcal disease in adults
Country Study period Study population 
Hong Kong 2000–200411 Adults aged >65 years with laboratory dat
Hospital Authority in Hong Kong
Malaysia 1994–199512 Patients with clinical infections (mainly C
hospitals in ﬁve geographic regions; 59% 
2006–200713 Patients with pneumococcal disease from
Singapore 1995–200414 4275 hospitalization records of patients a
years (64% >15 years) from all Singapore
Taiwan 1998–200515 All adults aged 18 years hospitalized wi
(N = 477 541); data from the National Hea
Research Database
200611 Data from the Bureau of National Health 
2000–200816 328 patients hospitalized in the National T
Hospital
Thailand 2003–200517 3910 patients (all ages) enrolled from the 
and Sa Kaeo provinces
2004–200618 4993 patients aged <5 to >65 years with




Population-based survey in the provinces
Phanom and Sa Kaeo by the Ministry of P
International Emerging Infections Program
2005–200719 23 853 hospitalized patients from the Nak
Sa Kaeo provinces with indications for blo
aged <5 years)
CAP, community-acquired pneumonia; IPD, invasive pneumococcal disease.
a There were no incidence data published in English for China, India, Indonesia, Japapneumonia) from all Singapore hospitals over 10 years found an
overall incidence of 10.9 per 100 000 population, with 56.4 per
100 000 in those aged >65 years.14 In Taiwan, an 8-year analysis of
4275 nationwide hospital admissions for community-acquired
pneumonia (CAP) found an annual incidence of 36.5 admissions
per 10 000 in 2004.15 According to the Taiwan Department of
Health, the incidence of IPD was 216 per 100 000 in the overall
population, and was 1147 per 100 000 in adults aged >65 years.11
In Malaysia, the estimated incidence of all-cause pneumonia was
20.406 hospitalizations per 1000 population in adults aged >65
years.13
The rural provinces of Nakhon Phanom and Sa Kaeo account for
approximately 2% of the total population of Thailand.17 In these
provinces, one study reported the incidence of all-cause radio-
graphically conﬁrmed pneumonia as 34.7 per 100 000 aged 50
years.17 In a second study conﬁned to the Nakhon Phanom
province from a similar period, however, the annual incidence of
radiographically conﬁrmed pneumonia in the overall population
ranged from 199 to 256 per 100 000 and from 717 to 877 per
100 000 in adults aged >65 years.18 A population-based survey
reported the incidence of IPD as 26 per 100 000 aged 75 years,11
while the incidence of hospitalized pneumococcal bacteremia was
3.7 and 7.6 per 100 000 in Sa Kaeo and Nakhon Phanom,
respectively.19
Mortality data were available for the above ﬁve countries, and
also for India, Japan, and South Korea, but data published in English
were lacking for China, Indonesia, Pakistan, the Philippines, and
Vietnam. The Asian Network for Surveillance of Resistant
Pathogens (ANSORP) has published several studies. In their most
recently published study of CAP in 955 adults from eight countries,
the overall mortality was 7.3%.20 In another study of 255
Asian adults with antibiotic-resistant pneumococcal pneumonia,, by countrya and by study
Incidence
a collated by the IPD annual incidence: 7.7/100 000
AP) from six
aged >10 years
Overall incidence of invasive and non-invasive
Streptococcus pneumoniae infections: 75.4/100 000
 six hospitals In adults aged 20 years, annual incidence per 1 000
population: pneumococcal pneumonia: 7.784;
pneumococcal bacteremia: 3.278; pneumococcal
meningitis: 0.108
Hospitalization rate in adults aged >65 years: 20.406 per
1000 population
ged <1 to 75
 hospitals
Mean annual hospitalization rate with pneumococcal




Mean monthly admission rate for CAP during whole study
period: 3.27/10 000
Annual incidence of admissions with CAP: 36.5/10 000 in
2004
Insurance IPD incidence: (i) overall: 216/100 000; (ii) in adults aged
>65 years: 1147/100 000
aiwan University IPD incidence among those hospitalized: (i) from 2000 to
2005: 6.2/10 000; (ii) from 2006 to 2008: 3.8/10 000
Nakhon Phanom Adjusted (for enrolment) annual incidence of
radiographically conﬁrmed pneumonia: (i) 5–49 years: 3.1/
100 000; (ii) 50 years: 34.7/100 000
 pneumonia
 Phanom
Annual incidence of radiographically conﬁrmed
pneumonia: (i) overall: 199–256/100 000; (ii) in adults
aged >65 years: 717–877/100 000
 of Nakhon
ublic Health and
IPD incidence in adults aged 75 years: 26/100 000
hon Phanom and
od culture (31%
Annual incidence of hospitalized pneumococcal
bacteremia: (i) Nakhon Phanom: 7.6/100 000; (ii) Sa Kaeo:
3.7/100 000
n, Pakistan, the Philippines, South Korea, and Vietnam.
Table 2
Summary of the mortality from pneumonia and invasive pneumococcal disease in adults, by countrya and by study
Country Study period Study population Mortality
Hong Kong 1995–200122 N = 214; mean age 40  33.7 years;
pneumococcal bacteremia
27.3% overall; 50.6% for adults aged >65 years
India 1999–200123 N = 2222; randomly selected death records All-cause pneumonia overall mortality: 3.7%
2000–200124 N = 70; 17–93 years; CAP 11%
1998–200025 N = 100; 15–80 years; CAP 14%
1993–200326 N = 564; median age 45 years; IPD 30%
Japan 1947–200927 General population in Japan Deaths from all-cause pneumonia in 2010: 94.1/100 000
2003–200528 N = 156; adult; CAP 5.1%
2001–200329 N = 156; adult; CAP 1.9%
2000–200230 N = 124; adult; CAP 5.6%
1998–200031 N = 231; 15 years; CAP 8.7%
1994–199732 N = 318; >15 years; CAP 6.1%
2006–200733 N = 496; 61% adults; IPD Mortality in adults: 22.1%
1997–200134 N = 306; median age 65.5 years; pneumococcal pneumonia 1.3%
Malaysia 1997–199935 N = 127; >12 years (mean 55.5 years); CAP Overall mortality: 10.2%; 2/13 (15.4%) patients who
died had pneumococcal bacteremia
1999–200913 Overall mortality: 10.4%
Singapore 1995–200414 N = 4275; <1 to 75 years (64% >15 years);
pneumococcal disease
Overall: 3.2%; in adults aged 75 years: 8.4%
2000–20078 N = 192; 14–96 years (median 64 years); Streptococcus
pneumoniae isolates causing invasive disease
Mortality from pneumococcal septicemia: 21.4%
2000–200136 N = 38; 14–90 years (median 57 years); Streptococcus
pneumoniae bacteremia
13.1%
South Korea 200837 N = 345; HCAP and CAP HCAP mortality: 19.2%; CAP mortality: 7.4%
1997–200038 N = 562; mean age 59.9 years; CAP 7.1%
2002–200739 N = 168; IPD 18.6%
1997–200640 N = 59; >16 years; pneumococcal bacteremia in patients
with liver cirrhosis
30-day mortality: 16.9%
1996–200141 N = 149; adults; pneumococcal bacteremia 23.8%
Taiwan NR42 Taiwan population Mortality rate for pneumonia: 23.6/100 000
NR43 N = 348 younger adults; N = 438 elderly patients; N = 201
very old patients (age 85 years)
30-day mortality rate was 5.2% in younger adults, 7.1% in
elderly patients, and 9.5% in very old patients
2004–200844 N = 134; all ages; non-bacteremic CAP Overall 6%, but all deaths occurred in patients
aged 65 years (i.e., mortality rate 27.6% in this age group)
2000–200845 N = 87; bacteremic CAP 30-day mortality: 14.9%
2004–200845 N = 87 non-bacteremic CAP; N = 134 bacteremic CAP
(same population as above)
The overall mortality rates at 7, 14, and 30 days were
signiﬁcantly higher in bacteremic than non-bacteremic
patients (12.6% vs. 2.2%, 14.9% vs. 3.7%, 19.5% vs. 5.1%,
all p < 0.01)
2001–200246 N = 168; mean age 56.1 years; CAP 8.3%
2000–200816 N = 328; IPD Overall mortality 2000–2005: 24.4%
Overall mortality 2006–2008: 21.8%
2000–200147 N = 53; 58.5% adults; IPD Mortality in adults: 35.5%
2000–200848 N = 265; community-acquired IPD 30-day mortality: 40.5%
1986–200149 N = 269 with bacterial meningitis of whom
N = 22 (all adult) with Streptococcus pneumoniae
Pneumococcal meningitis: 50%
1986–198950 N = 38; 17–75 years; streptococcal meningitis Pneumococcal meningitis: 52.6%
Thailand 1985–200451 Total elderly Thai population (aged >60 years) Mortality due to pneumonia in 2003: 107.4/100 000
2004–200618 N = 4993; <5 to >65 years; pneumonia requiring
hospitalization
Overall mortality: 6.9/100 000; in-patients >65 years:
44/100 000
IPD, invasive pneumococcal disease; CAP, community-acquired pneumonia; HCAP, healthcare-associated CAP; NR, not reported.
a There were no mortality data published in English for China, Indonesia, Pakistan, the Philippines, and Vietnam.
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pneumonia.21 The most common comorbidities in both studies
were bronchopulmonary disease, cardiovascular disease, malig-
nancy, and diabetes mellitus; adult patients with these illnesses
may be at higher risk of contracting pneumonia and IPD.
The principle studies reporting mortality data by country are
summarized in Table 2. In general, mortality from CAP was <10%,
but appeared slightly higher (11–14%) in India,24,25 as well as in
patients with bacteremic CAP (14.9%)45 and in elderly patients
(27.6%).44 Mortality from IPD ranged from approximately 18% in a
South Korean study39 to 40% for community-acquired IPD in
Taiwan;48 IPD-related mortality in a relatively large, recent,
Japanese study was 22%,33 and in a similarly large Indian study
was 30%.26 In 2009, pneumonia was the fourth leading cause of
death in Ministry of Health hospitals in Malaysia, with 10.4% of
hospital mortality.13 Mortality from pneumococcal meningitis was
approximately 50% in two Taiwanese studies.49,503.2. Clinical characteristics and outcomes of S. pneumoniae as the
etiological agent
In the published studies identiﬁed, the etiology of the
pneumonia was often either not determined at all, or if
determined, the proportion of cases for which any etiological
agent could be found was low. The study populations were
typically small (<50–200). The ﬁndings often varied widely within
countries, reﬂecting differences in study population demographics
and in the efﬁciency or methodology of detecting causative
pathogens. We found only a single published study that included
the etiology of IPD.
The incidence of S. pneumoniae detected as the causative agent
of CAP, IPD, and bacterial meningitis, as well as that associated
with other conditions, is summarized in Table 3. In India, South
Korea, Taiwan, Thailand, and Japan, as well as in a pan-Asian study,
S. pneumoniae was the most common pathogen associated with
Table 3
Summary of the incidence of Streptococcus pneumoniae as etiological agent by
clinical condition and country






















Otitis media Taiwan15 44.0
Stroke-associated pneumonia Pakistan71 3.9
CAP, community-acquired pneumonia; IPD, invasive pneumococcal disease.
a Patients in this study were diagnosed with streptococcal meningitis.
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pneumoniae increased the risk of mortality and extrapulmonary
involvement in patients with pneumococcal CAP.45 In another
study in Taiwan, elderly patients were more likely to have atypical
clinical manifestations and worse outcomes. In this study, the 30-
day mortality rate was 5.2% in younger adults, 7.1% in elderly
patients, and 9.5% in very old patients (85 years).43 In Japan and
Singapore, S. pneumoniae was the most common causative agent of
CAP in some but not all studies, while in China and Malaysia, S.
pneumoniae was not the most frequently-associated etiological
agent. Studies from India, Japan, Singapore, and Taiwan have
reported that S. pneumoniae accounted for 69%, 19%, 27%, and 8%,
respectively, of bacterial meningitis cases.33,49,50,67–69 In a recent
study in Japan, CAP was associated with better outcomes and a
lower 30-day mortality rate compared to the nursing home-
acquired pneumonia group.72
3.3. Serotype prevalence
Pneumococcal serotype prevalence varied widely between and
within countries. For countries such as Indonesia and Vietnam, the
only published data on serotype prevalence have come from
multinational studies conducted a decade ago involving very small
numbers of isolates from single centers within each country. These
data may therefore not reﬂect the current serotype prevalence in
these countries. No serotype prevalence data could be found for
Pakistan. In China, the prevalent serotypes were 19F, 19A, 6B, 23F,
14, and 6A in isolates taken from 2009 to 2010.73 In a recent report
from Thailand, out of 172 isolates taken between 2006 and 2009,
the most common serotypes were 6B, 23F, 14, 19F, and 19A in
patients <5 years old, and 6B, 19A, 23F, 4, and 9 V in patients >65
years old.74 Another study from Thailand found that, at the
Phramongkutklao Hospital in Bangkok, the most common serotype
in patients from 2004 to 2008 was 6B.75
In Hong Kong, the most common serotypes identiﬁed in the
studies reviewed here were 23F, 19F, 14, 6A, and 6B (in
approximate order of decreasing prevalence); note that these
studies were carried out between 1995 and 2001.76 Several studies
on serotype prevalence in India consistently showed serotype 1 tobe the most prevalent amongst adults, with other common
serotypes being 5, 6, 7, and 19.26,77–79 In Japan, serotypes 19F, 23F,
3, 6A, and 6B were consistently predominant in older studies.80–84
The most recent Japanese study, carried out from 2006 to 2007,
showed that 12F, 3, 6B, and 14 were the most prevalent
serotypes.39 The most common serotypes identiﬁed in Malaysia
were 19F, 19A, 23F, 6A, and 6B in studies between 1999 and
2008.12,85–88 Serotypes 1, 6B, 19B, and 19F were predominant in an
older study dating from 1994 to 1995.12
Serotype prevalence among S. pneumoniae isolates in Singapore
varied in the most recently published studies. A study of invasive
isolates collected between 2000 and 2007 showed that serotypes
14, 3, 6B, 8, and 19F were the most common, comprising 51.1% of
the total number of isolates.8 In a 2009 study, serotypes 7F, 3, and
19A were most frequent among adults, accounting for 45.3% of
adult IPD cases.89 Multi-country studies predating 2001 found that
23, 19, 6, and 14 were the most prevalent serogroups in
Singapore.86,87,90,91
Serotypes 19F and 23F were consistently the most commonly
identiﬁed in all South Korean studies,91–94 although a 2009 study
shows that their combined prevalence decreased from approxi-
mately 50% in 2000 to 15% in 2007.94 In Taiwan, the most common
serotypes consistently identiﬁed in adults over the past decade
include 23F, 19F, 14, 6B, and 3,44,86,87,95–100 which together
generally account for over 80% of S. pneumoniae isolates.
3.4. Antibiotic resistance
In global multi-country studies of antimicrobial susceptibility
in S. pneumoniae, regional rates of antibiotic resistance were
consistently the highest in Asia.101–103 In the two most recently
published studies of antibiotic resistance by ANSORP, which
include individual country data from multiple Asian countries,
isolates from China, Hong Kong, South Korea, Taiwan, Thailand,
and Vietnam generally had the highest antibiotic resistance rates,
although it should be noted that these studies were carried out a
decade ago.86,87 More detailed results from these studies are
discussed by country below. Recent (within the last decade),
reliable antibiotic resistance data were not found for S. pneumoniae
isolates from adults in Indonesia or Pakistan. It is important to note
that the Clinical and Laboratory Standards Institute (CLSI)
published a set of new S. pneumoniae breakpoints for penicillin
in 2008.104 Therefore, only studies on penicillin resistance
published after 2008 were reviewed.
In China, erythromycin resistance rates for S. pneumoniae
increased from 35–53% in 1996–1999, to over 75% by
2001.86,87,105,106 Among isolates collected during 1999–2000,
levoﬂoxacin resistance was 3.3%, and this increased to 6.8% by
2002.105,107 In a recent report, approximately 10%, 30%, 70%, 25%,
and 40% were resistant to the beta-lactam antibiotics penicillin,
amoxicillin, cefuroxime, ceftriaxone, and meropenem, respective-
ly, and 96% were resistant to erythromycin and clindamycin. The
majority of isolates were also resistant to tetracycline (84%) and to
co-trimoxazole (74%).73
Hong Kong has some of the highest antibiotic resistance rates
for S. pneumoniae in the world. Erythromycin resistance rates
increased above 70% in separate surveillance studies conducted
between 1998 and 2001.86,87 Levoﬂoxacin resistance peaked
around 1999–2000 at rates of up to 14.3%, then decreased to
5.1% in 2007.22,102,107,108 With the new penicillin breakpoint, a
recent study showed that 66.9% and 97.8% of the isolates from
adults were penicillin-sensitive at the meningitis and non-
meningitis breakpoints, respectively.109
Antibiotic resistance levels reported in the Indian studies were
lower than in many other Asian countries. An Indian multicentre
surveillance study published in 1999 reported resistance rates of
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chloramphenicol.3 In Japan, penicillin-resistant S. pneumoniae
was isolated in 12.5% of non-hospital-acquired pneumonia cases in
a recent retrospective study.110 Erythromycin resistance rates
were reported to be around 80% in the more recently published
studies, which are among the highest in the world.28,111–114
A recent study in Malaysia showed that serotype 19F had
increased antibiotic resistance and was highly invasive.88 This
study also found that out of 151 clinical isolates, 21.2% were
penicillin-resistant S. pneumoniae strains, 29.1% penicillin-inter-
mediate, and 49.7% penicillin-susceptible,88 whereas another
study published in 2011 estimated the penicillin resistance rate
to be higher, at 31.78%.115 Besides, erythromycin resistance rates
also appeared to be increasing from 3% (1996–1997) to 36.8%
(1998–2001).86,87,116 The most recent data on antibiotic resistance
in Singapore were published between 1995 and 2001. In multi-
country studies that included small numbers of isolates from
Singapore, the highest levels of antibiotic resistance were reported
against erythromycin (52.9%) and cefuroxime (28.6%).86,87
A number of studies showed that resistance rates to erythro-
mycin in South Korea remained high over the period 1996–2001
(75–85%).86,87 Interestingly, a recent report analysis from South
Korea found that antibiotic non-susceptibility did not have an
effect on mortality in adult patients with pneumococcal bacter-
emia.117 Despite the Taiwanese government issuing a directive to
reduce antibiotic usage in 2001, which resulted in a 45% decrease
in macrolide consumption between 1999 and 2001,96 erythromy-
cin resistance remained high at 94%.118 Non-susceptibility to
levoﬂoxacin increased from 1.2% in 2001 to 4.2% in 2007.98
In a recent study in Thailand, 92% of the sterile site isolates were
penicillin-susceptible.64 In contrast, high resistance rates to co-
trimoxazole (>50%) and erythromycin (>40%) were
reported.19,119–121 A recent study provided the ﬁrst data on the
mechanisms of ﬂuoroquinolone resistance in S. pneumoniae in
Thailand and the resistance rate remained low at 6.5%.122 In two
multinational antimicrobial susceptibility studies carried out
between 2000 and 2004, Vietnam’s isolates had one of the highest
resistance rates against cefuroxime, clindamycin, and erythromy-
cin out of 11 Asian countries.87,123,124
3.5. Current pneumococcal disease prevention strategies
The ﬁrst vaccine available for immunization of adults was the
plain PPV23. Plain polysaccharide vaccines, such as PPV23,
appear to have a limited duration of efﬁcacy against invasive
pneumococcal disease,125 and there is inconsistent evidence that
PPV23 is effective against non-bacteremic CAP.126–128 Further-
more, PPV23 does not decrease nasopharyngeal carriage, a
substantial source of transmission of pneumococci, and thus may
fail to generate herd immunity.129 Such an effect remains to be
reported. In addition, revaccination with PPV23 appears to result
in a lower functional immune response compared with the
responses after initial immunization.130,131 This could be
explained by the down-regulation of memory B-cells, particu-
larly the B1b cell subset, leading to B-cell depletion of the PPV23.
This phenomenon is partially reversible by the PCV.132 PPV23 is
almost exclusively administered to adults, although its efﬁcacy
remains controversial.133–136
The immunological limitations of polysaccharide vaccines can
be overcome with pneumococcal conjugate vaccines.132 PCVs have
been shown in infants and children to induce long-term protection,
immunological memory, and herd immunity.137–139
Of the two existing pneumococcal conjugate vaccines, PCV10
and PCV13 (Prevnar 131), only PCV13 has recently been approved
by the United States Food and Drug Administration, the European
Union, and many other countries for use in adults aged 50 years.The clinical program for PCV13 has demonstrated that when
administered as the ﬁrst pneumococcal vaccine to adults aged 50
years, or when administered to those previously immunized with
PPV23, PCV13 provides the immunologic advantages associated
with conjugate vaccines, and thus has the potential for improved
efﬁcacy against pneumococcal disease compared to the PPV23
vaccine.140,141
Since the introduction of conjugate vaccines in the USA, rates of
pneumococcal disease have decreased among persons of all ages,
including those aged 65 years.7 Further, rates of pneumococcal
meningitis have decreased in children <5 years of age (reduction
from 97 cases per 100 000 population during 1998–1999 to 24
cases per 100 000 in 2005; disease caused by vaccine-type strains
fell from 80 cases per 100 000 population to 4.6)142 and also in
adults since PCV7 was introduced in the USA.143 The reduction in
pneumococcal disease in the adult population >65 years old
reported in the USA appears to be the result of an increase in herd
immunity.144
Information regarding the beneﬁts of current pneumococcal
vaccination strategies was found for Malaysia, Taiwan, Singapore,
China, Japan, Thailand, South Korea, and Hong Kong. In Malaysia, a
recent Pﬁzer-sponsored study determined that at current vaccine
prices, PCV7 vaccination of 90% of a hypothetical 550 000 birth
cohort would incur costs of 439.6 million RM ($128 million
USD).13 The study concluded that vaccination would reduce
episodes of pneumococcal hospitalization by 9585 cases (taking
into account both the pediatric population and the impact of herd
protection in the adult population) to 73 845 hospitalizations,
with cost savings of 37.5 million RM ($10.9 million USD) to the
health system, and with 11 422.5 life-years saved (in pediatric and
adult populations together), at a cost-effectiveness ratio of 35 196
RM ($10 261 USD) per life-year gained.13 In Taiwan, a hospital-
based surveillance of IPD in a medical center was conducted from
2000 to 2008 to evaluate the epidemiologic changes after
pneumococcal vaccination with PPV23 and PCV7. The cumulative
coverage rate of PPV23 among persons aged 75 years increased
from 12% in 2007 to 41% in 2008, and that of PCV7 among children
<5 years old was 0.7% in 2005 and 25.2% in 2008. The annual
incidence of IPD decreased from 6.2 cases per 10 000 hospitaliza-
tions in 2000–2005 to 3.8 cases in 2006–2008 (38.5% reduction,
p < 0.001), but the fatality rate did not change signiﬁcantly (24.4%
and 21.8%, p = 0.74).16
In a recent cost-effectiveness estimate of pneumococcal
vaccination in Singapore, PCV13 prevented 834 cases and seven
deaths due to pneumonia, meningitis, and bacteremia in the
vaccinated population, and 952 cases and 191 deaths in the
unvaccinated population (due to herd effects) over the 5-year time
period.145 The calculated cost-effectiveness ratio for PCV13 was
$37 644 USD ($51 854 SGD) per quality-adjusted life-year (QALY).
The PCV7 cost per QALY was $43 275 USD ($59 610 SGD).145
These estimates demonstrate that pneumococcal vaccination in
Singapore is cost-effective, especially when considering the impact
of herd immunity. Similar results were demonstrated in a Markov
state-transition model conducted in the USA.146
A study in China at a single hospital during 2009–2011 showed
that the majority of pneumococcal isolates (76%) were of serotypes
included in the PCV13.73 A recent report from Japan showed that
PPV23 vaccination in adults signiﬁcantly reduced medical costs for
all study subjects during the ﬁrst year (p = 0.027). This study also
demonstrated that PPV23 was effective for all-cause pneumonia
for study subjects >75 years of age, although the effect was not
signiﬁcant for all study subjects >65 years of age.147 Another
recent Japanese study found that PPV23 vaccination of nursing
home residents signiﬁcantly reduced the incidence of pneumo-
coccal pneumonia and all-cause pneumonia when compared with
placebo (p  0.001), as well as the death rate from pneumococcal
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did not differ between the two groups.136
In Thailand, PCV7 covered 70.3%, 43.6%, and 43.5% of patients
aged <5, 5–64, and 65 years, respectively, while PCV13 covered
81.2%, 59.7%, and 60.9%, respectively.124 In South Korea, the
pneumococcal carriage rate was 18% in subjects who were
vaccinated with PCV7 vs. 31.5% in unvaccinated subjects.148
Multidrug resistance was also lower in vaccinated subjects
compared with unvaccinated subjects. Another study showed
that since PCV7 introduction to Korea, PCV7 serotypes decreased
signiﬁcantly from 66.8% in 1996–2001 to 41.3% in 2008–2009.149
However, non-PCV7 serotypes have been increasing, and some
clones are becoming antibiotic-resistant. A multi-country study
found that among 19A isolates from 10 Asian countries, the
prevalent clone was multidrug-resistant ST320.150 Changing
serotypes due to the introduction of vaccines is important to
consider for future vaccination strategies in these regions.
Dual vaccination of PPV23 and trivalent inactivated inﬂuenza
vaccine (TIV) is recommended by the World Health Organization
for elderly, chronically ill populations; however, in many Asian
countries vaccination rates are low due to doubts regarding the
effectiveness of dual vaccination. The cost-effectiveness of dual
vaccine administration has already been demonstrated in the
USA.9 A recent study from Hong Kong demonstrated the
effectiveness and clinical impact of dual vaccination in elderly
patients.10 Dual vaccinations resulted in fewer coronary (hazard
ratio (HR) 0.59, 95% conﬁdence interval (CI) 0.44–0.79; p < 0.001)
and intensive care admissions (HR 0.45, 95% CI 0.22–0.94;
p = 0.03), compared with unvaccinated subjects. Dual vaccination
with PPV23 and TIV was shown to be effective in reducing the
development of complications from respiratory, cardiovascular,
and cerebrovascular diseases in elderly patients with chronic
illnesses.10 Currently, there is free coverage with the PPV23
vaccination for high-risk groups in Hong Kong.151 Dual vaccination
is important to consider in elderly, chronically ill patients to reduce
hospitalization, coronary or intensive care admissions, and death.
4. Conclusions
Determining the true incidence and mortality of pneumococcal
disease amongst adults in many Asian countries is constrained by
the wide variation in study quality and design, and variations in the
sizes and demographics of the study population. Often, study
populations were small (<50–200), studies were carried out in
only one or two centers, or they were carried out a decade ago or
before PCVs became widely used. Hence these data may not be
representative of the current situation over the entire country in
many cases. Furthermore, it is possible that further epidemiologi-
cal data are available for China, Japan, and South Korea, but have
not been published in English.
The countries with the most comprehensive epidemiological
data on adult pneumococcal disease are Taiwan and Thailand. The
ongoing surveillance program by the International Emerging
Infections Program in Thailand appears to be unique in Asia in
providing long-term information on the incidence, mortality, and
seasonality of pneumococcal disease in large populations, al-
though the data are limited to two large rural provinces where
surveillance is carried out. Very little relevant data on pneumo-
coccal disease of any kind could be found for Indonesia, Pakistan,
the Philippines, and Vietnam, and surveillance is urgently needed
in these countries. When setting up surveillance studies, the
methods used in Thailand and Taiwan are likely to be of use in
countries that lack comprehensive data on the burden and
epidemiology of pneumococcal disease in adults.
The antibiotic resistance status in countries was constrained by
a limited number of referral centers, and relatively few isolateswere involved in the studies and may not be an accurate reﬂection
of the true antibiotic resistance status of the country. The majority
of data on serotype prevalence and antimicrobial susceptibility in
S. pneumoniae in Asian adults were published by scientists from
Hong Kong, Taiwan, South Korea, and Japan, although studies were
also found from China, Thailand, Malaysia, Singapore, Vietnam,
and India. The most common studies often carried out detailed
molecular analyses to determine the mechanisms of antibiotic
resistance and the reasons behind its spread. Importantly, these
data highlight increased penicillin and multidrug resistance
among pneumococci as a serious problem in many countries in
the region and globally.
Overall, data were lacking on the economic burden of
pneumococcal disease in Asia. However, several recent studies
have shown decreases in economic burden of pneumococcal
disease after the introduction of vaccinations. The emergence and
spread of resistance emphasize the importance of vaccination to
prevent infection in adults at increased risk of serious pneumo-
coccal disease. While vaccination with PCV7, PCV13 in children,
PPV23 in adults, and dual PPV23/TIV vaccinations in elderly,
chronically ill individuals decreases the spread of pneumococcal
disease, leading to better clinical and economic outcomes, the
vaccination policies vary widely in Asia. There is a critical need for
increased awareness of the public health and economic beneﬁts of
pneumococcal vaccination, which will aid both the public and
policymakers in making changes to vaccination policies in the
region.
Observational studies have demonstrated that PPV reduces the
risk of IPD in immunocompetent elderly individuals, but neither
observational studies nor clinical trials have demonstrated
consistent evidence for a reduction in the incidence of pneumonia
in vaccinated older adults.
Conjugate vaccines may offer an advantage over polysaccharide
vaccines. Possible advantages of PCVs in elderly adults include
higher levels of protection against the vaccine serotypes after
vaccination and the ability to prolong the duration of protection by
use of repeated vaccinations over time. The effectiveness of PCVs
against pneumonia in children also raises the possibility that PCVs
may protect against non-bacteremic pneumococcal pneumonia in
adults. A limitation of PCVs, however, is that fewer serotypes are
included in those vaccines than in PPV.
Providing as many individuals as possible access to pneumo-
coccal vaccines will decrease the overall number of hospitaliza-
tions, complications, and deaths associated with pneumococcal
disease.
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